28 genetic-algorithm Fellowship positions at Northeastern University

Alnylam Pharmaceuticals-Global Medical Affairs Early Assets Postdoctoral Research Fellow

Northeastern University | Boston, Massachusetts | United States | 3 days ago

with rare and more prevalent diseases. Based on Nobel Prize-winning science, RNAi therapeutics represent a powerful, clinically validated approach to treating diseases at their genetic source by

Alnylam Pharmaceuticals-Clinical Science Postdoctoral Research Fellow

Northeastern University | Boston, Massachusetts | United States | 3 days ago

prevalent diseases. Based on Nobel Prize-winning science, RNAi therapeutics represent a powerful, clinically validated approach to treating diseases at their genetic source by “interfering” with mRNA

Alnylam Pharmaceuticals- US Marketing Postdoctoral Research Fellow

Northeastern University | Boston, Massachusetts | United States | 3 days ago

prevalent diseases. Based on Nobel Prize-winning science, RNAi therapeutics represent a powerful, clinically validated approach to treating diseases at their genetic source by “interfering” with mRNA

Alnylam Pharmaceuticals-US Medical Affairs Postdoctoral Research Fellow

Northeastern University | Boston, Massachusetts | United States | about 1 month ago

to treating diseases at their genetic source by 'interfering' with mRNA that cause or contribute to disease. Since our founding in 2002, Alnylam has led the RNAi Revolution and continues to turn scientific

Alnylam Pharmaceuticals-Regulatory Affairs Postdoctoral Research Fellow

Northeastern University | Boston, Massachusetts | United States | about 1 month ago

approach to treating diseases at their genetic source by 'interfering' with mRNA that cause or contribute to disease. Since our founding in 2002, Alnylam has led the RNAi Revolution and continues to turn

Alnylam Pharmaceuticals-Global Medical Information Postdoctoral Research Fellow

Northeastern University | Boston, Massachusetts | United States | about 2 months ago

validated approach to treating diseases at their genetic source by 'interfering' with mRNA that cause or contribute to disease. Since our founding in 2002, Alnylam has led the RNAi Revolution and continues

Alnylam Pharmaceuticals- US Marketing Postdoctoral Research Fellow

Northeastern University | Boston, Massachusetts | United States | about 2 months ago

at their genetic source by 'interfering' with mRNA that cause or contribute to disease. Since our founding in 2002, Alnylam has led the RNAi Revolution and continues to turn scientific possibility into reality. Our

Postdoctoral Research Fellow, Alnylam--Regulatory Affairs

Northeastern University | Boston, Massachusetts | United States | 3 months ago

diseases. Based on Nobel Prize-winning science, RNAi therapeutics represent a powerful, clinically validated approach to treating diseases at their genetic source by “interfering” with mRNA that cause